| Literature DB >> 25958245 |
Chris Dockendorff1, Patrick W Faloon2, Andrew Germain2, Miao Yu3, Willmen Youngsaye2, Partha P Nag2, Melissa Bennion2, Marsha Penman3, Thomas J F Nieland3, Sivaraman Dandapani2, José R Perez2, Benito Munoz2, Michelle A Palmer2, Stuart L Schreiber4, Monty Krieger5.
Abstract
A new series of potent inhibitors of cellular lipid uptake from HDL particles mediated by scavenger receptor, class B, type I (SR-BI) was identified. The series was identified via a high-throughput screen of the National Institutes of Health Molecular Libraries Small Molecule Repository (NIH MLSMR) that measured the transfer of the fluorescent lipid DiI from HDL particles to CHO cells overexpressing SR-BI. The series is characterized by a linear peptidomimetic scaffold with two adjacent amide groups, as well as an aryl-substituted heterocycle. Analogs of the initial hit were rapidly prepared via Ugi 4-component reaction, and select enantiopure compounds were prepared via a stepwise sequence. Structure-activity relationship (SAR) studies suggest an oxygenated arene is preferred at the western end of the molecule, as well as highly lipophilic substituents on the central and eastern nitrogens. Compound 5e, with (R)-stereochemistry at the central carbon, was designated as probe ML279. Mechanistic studies indicate that ML279 stabilizes the interaction of HDL particles with SR-BI, and its effect is reversible. It shows good potency (IC50=17 nM), is non-toxic, plasma stable, and has improved solubility over our alternative probe ML278.Entities:
Keywords: Cholesterol transport; HCV; HDL receptor; ML279; SR-BI inhibitor
Mesh:
Substances:
Year: 2015 PMID: 25958245 PMCID: PMC4469081 DOI: 10.1016/j.bmcl.2015.03.074
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823